Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Laroni A, Lapucci C, Da Rin G, Serrati C, Gandoglia I, Tassinari T, Perego G, Brichetto G, Gazzola P, Mannironi A, Stromillo ML, Cordioli C, Landi D, Clerico M, Signoriello E, Frau J, Ferrò MT, Di Sapio A, Pasquali L, Ulivelli M, Marinelli F, Callari G, Iodice R, Liberatore G, Caleri F, Repice AM, Cordera S, Battaglia MA, Salvetti M, Franciotta D, Uccelli A; CovaXiMS study group on behalf of the Italian Covid-19 Alliance in MS.
Sormani MP, et al. Among authors: inglese m.
EBioMedicine. 2021 Oct;72:103581. doi: 10.1016/j.ebiom.2021.103581. Epub 2021 Sep 22.
EBioMedicine. 2021.
PMID: 34563483
Free PMC article.